Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Inclusion criteria: * A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia * Evaluable disease or measurable disease * Transfusion independent * Able to take oral medication * Male and Female subjects \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Women of childbearing potential using adequate contraception Exclusion criteria: * Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse events necessitating treatment discontinuation * Eligible for a hematopoietic stem cell transplant (HSCT) * The subject has received investigational or non-investigational cytotoxic chemotherapy (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g. ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4 weeks prior to Cycle 1, Day 1 * Radiation therapy within 2 weeks prior to Cycle 1, Day 1 * Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks * Prior allogeneic HSCT * Active central nervous system (CNS) metastases or leptomeningeal involvement * Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV) * Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection * Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g. pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine) * Diagnosis or treatment for another malignancy within 3 years of enrollment with the exception of complete resection of basal cell or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy * Inadequate bone marrow function * Abnormal liver function * Abnormal renal function * Abnormal coagulation The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.